Corporate Finance, Securities and Capital Markets

Corporate Finance, Securities and Capital Markets

Meitar is Israel’s leading law firm in securities and capital markets. We represent issuers, underwriters and investors in all stages of initial and secondary public offerings of equity, debt and hybrid securities in the US, Europe and Israel.  Most of our partners have trained previously in corporate departments of leading international law firms, and we offer clients the knowledge and understanding of the public offering process both in Israel and abroad.  Our work in capital markets has received the top Israeli ranking from Chambers & Partners, Legal 500 and other leading guides, and we have been ranked by IPO Journal as the non-US law firm with the largest number of initial public offerings in US capital markets.

As part of our securities practice, we regularly address complex legal issues that arise in the context of public offerings, including the use of sophisticated and novel financial instruments. We also advise on compliance with securities regulations and assist clients in the preparation of the various types of securities filings and reporting under US, UK and Israeli securities laws.

Representative experience

Issuer Counsel:

• Representation of SolarEdge Technologies, Inc. in its $126 million initial public offering on NASDAQ.
• Representation of Kornit Digital in its $106 million initial public offering on NASDAQ.
• Representation of CyberArk in its $86 million initial public offering on NASDAQ (September 2014).
• Representation of Mobileye in the Largest Israeli IPO ever on NYSE raising $890 million (before the potential sale of additional shares by underwriters) (August 2014).
• Representation of Macrocure in its $54 million initial public offering on NASDAQ (July 2014).
• Representation of  ‘MediWound’ in its $80 million initial public offer on NASDAQ (March 2014)
• Representation of Lumenis in its $84 million public offering of ordinary B shares and listing on NASDAQ (March 2014).
• Representation of Enzymotec in its $151 million secondary follow-on public offering on NASDAQ (February 2014).
• Representation of Stratasys in its $481 million follow-on public offering of Ordinary Shares on NASDAQ (2013).
• Representation of Enzymotec in its $70 million initial public offering on NASDAQ (2013).
• Representation of Evogene in its $73.8 million initial public offering on NYSE (2013).
• Representation of Sapiens in its $40 million follow-on public offering of common shares on NASDAQ (2013).
• Representation of Cimatron in its $13.6 million secondary and $5.4 million follow-on public offerings of ordinary shares on NASDAQ (2013).
• Representation of Objet in a contemplated IPO on NASDAQ, which in its advanced stages was deferred, in a dual-tracking process, in favor of entering into an all-stock merger of equals with Stratasys, a Delaware corporation (NASDAQ:SSYS) (2012).
• Representation of Gazit-Globe (TASE: GLOB; NYSE: GZT), one of the largest owners and operators of supermarket-anchored shopping centers in the world, in its $81 million initial public offering in the New York Stock Exchange (2011).

Underwriters’ Counsel:

• Representation of Barclays Capital and several other underwriters in the $40 million initial public offering of ReWalk (September 2014).
• Representation of Barclays Capital and several other underwriters in the contemplated $40 million public offering of Magic Software (2014).
• Representation of Morgan Stanley, Barclays Capital and several other underwriters in the $106 million initial public offering of Varonis (2014).
• Representation of J.P Morgan Securities, Merrill Lynch and several other underwriters in the $127 million initial public offering of Wix.com, including both primary and secondary shares (2013).
• Representation of Barclays Capital and several other underwriters in the $70 million initial public offering of Mazor (2013).
• Representation of Roth Capital Partners in the $20 million follow on offering of Attunity Ltd. (2013).
• Representation of Needham & Company and Oppenheimer & Co. in the $32 million ordinary shares of Ceragon Networks (2013).
• Representation of Citigroup Global and Barclays Capital in the $1.4 billion global notes offering by Israel Electric Corporation (2013).
• Representation of UBS, Barclays Capital and Citigroup in the $1.5 billion global notes offering by the State of Israel (2012).
• Representation of UBS and Barclays Capital in the $500 million global notes offering by Israel Electric Corporation (2012).
• Representation of Barclays Capital, Goldman Sachs and Morgan Stanley in the $750 million debt offering by Teva Pharmaceutical Industries (March 2011).
• Representation of Barclays Capital, Citigroup, Goldman Sachs and Morgan Stanley in the $5 billion debt offering by Teva Pharmaceutical Industries (November 2011).
• Representation of JP Morgan and Barclays Capital in the $84 million public offering of ordinary shares by Orbotech (2011).